*By Carlo Versano* Shares of SurveyMonkey's parent company SVMK ($SVMK) jumped more than 50 percent in their market debut Wednesday. The stock opened at $18.75, well above the IPO price of $12, which was already higher than the target range. It's just the latest sign of strong investor demand for new tech offerings ー SVMK also sold a greater-than-expected 15 million shares in the IPO. The 20-year old online polling company, part of the original dot-com rush, hopes to ride the wave of strong tech IPOs from the likes of Eventbrite ($EB), Farfetch ($FTCH), and Sonos ($SONO). "It seems like investors really can't get enough of these IPOs," said the Wall Street Journal's Maureen Farrell. Farrell has been following the SurveyMonkey road show and told Cheddar Wednesday "there was a ton of excitement," highlighted by a $40 million capital raise from Salesforce Ventures, which also invested in Dropbox ($DBX) in that company's March IPO. That was "another stamp of approval from the industry," Farrell said. SurveyMonkey was a pioneer of the "Freemium" model. The company said it had 16 million active users as of June, with 600,000 paying for the premium service. The company is not yet profitable, though ー like with many new tech companies ー that fact has not slowed interest. The company is also a natural acquisition target, according to Farrell. Cloud computing companies like Oracle ($ORCL) and Salesforce ($CRM) would be obvious suitors, with the latter already showing its interest. Among SurveyMonkey's largest shareholders is Facebook COO Sheryl Sandberg, who inherited a 10 percent stake when her husband, former SurveyMonkey CEO Dave Goldberg, passed away unexpectedly in 2015. Sandberg has said she will donate the entirety of her shares to The Sheryl Sandberg & Dave Goldberg Family Foundation.

Share:
More In Business
Walmart Introduces Calming Hours
Walmart announced it's looking to create a calm morning shopping experience by turning TV walls to static non-moving images, silencing radios, and dimming store lights.
Biogen Lowers Full-Year Profit Forecast
Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
Load More